Hagens berman, national trial attorneys, encourages investors in y-mabs therapeutics (ymab) with significant losses to contact the firm's attorneys, firm investigating possible securities law violations

San francisco, california--(newsfile corp. - november 4, 2022) - hagens berman urges y-mabs therapeutics, inc. (nasdaq: ymab) investors who suffered significant losses to submit your losses now.visit: www.hbsslaw.com/investor-fraud/ymab contact an attorney now: ymab@hbsslaw.com 844-916-0895y-mabs therapeutics, inc. (nasdaq: ymab) investigation: the investigation focuses on y-mabs' past assurances that its biologics license application ("bla") for i-omburtamab for the treatment of central nervous system/leptomeningeal metastases in
YMAB Ratings Summary
YMAB Quant Ranking